Validation pour Ingenuity407

vers la météo de la validation par utilisateur

Ingenuity407

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 71 - PMID ?

Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant SP with a homozygous knockout of SP NODE .

name="reponse" value="NA"> Non annotée
name="reponse" value="JSP"> Je ne sais pas
name="reponse" value="INS"> Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

<?php echo $Com ; ?>

name="reponse" value="A0">Analyse 0

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A1">Analyse 1

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A2">Analyse 2

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A3">Analyse 3

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A4">Analyse 4

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A5">Analyse 5

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A6">Analyse 6

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A7">Analyse 7

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A8">Analyse 8

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A9">Analyse 9

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A10">Analyse 10

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A11">Analyse 11

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A12">Analyse 12

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A13">Analyse 13

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A14">Analyse 14

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A15">Analyse 15

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A16">Analyse 16

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A17">Analyse 17

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A18">Analyse 18

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A19">Analyse 19

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A20">Analyse 20

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A21">Analyse 21

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A22">Analyse 22

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A23">Analyse 23

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A24">Analyse 24

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A25">Analyse 25

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A26">Analyse 26

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A27">Analyse 27

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A28">Analyse 28

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A29">Analyse 29

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A30">Analyse 30

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A31">Analyse 31

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A32">Analyse 32

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A33">Analyse 33

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A34">Analyse 34

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A35">Analyse 35

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A36">Analyse 36

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A37">Analyse 37

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A38">Analyse 38

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A39">Analyse 39

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A40">Analyse 40

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A41">Analyse 41

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A42">Analyse 42

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A43">Analyse 43

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A44">Analyse 44

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A45">Analyse 45

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A46">Analyse 46

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A47">Analyse 47

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A48">Analyse 48

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A49">Analyse 49

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A50">Analyse 50

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A51">Analyse 51

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A52">Analyse 52

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A53">Analyse 53

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A54">Analyse 54

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A55">Analyse 55

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A56">Analyse 56

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A57">Analyse 57

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A58">Analyse 58

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A59">Analyse 59

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A60">Analyse 60

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A61">Analyse 61

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A62">Analyse 62

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A63">Analyse 63

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A64">Analyse 64

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A65">Analyse 65

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A66">Analyse 66

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A67">Analyse 67

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A68">Analyse 68

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A69">Analyse 69

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A70">Analyse 70

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A71">Analyse 71

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A72">Analyse 72

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A73">Analyse 73

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A74">Analyse 74

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A75">Analyse 75

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A76">Analyse 76

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A77">Analyse 77

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A78">Analyse 78

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A79">Analyse 79

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A80">Analyse 80

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A81">Analyse 81

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A82">Analyse 82

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A83">Analyse 83

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A84">Analyse 84

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A85">Analyse 85

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A86">Analyse 86

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A87">Analyse 87

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A88">Analyse 88

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A89">Analyse 89

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A90">Analyse 90

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A91">Analyse 91

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A92">Analyse 92

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A93">Analyse 93

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A94">Analyse 94

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A95">Analyse 95

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A96">Analyse 96

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A97">Analyse 97

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A98">Analyse 98

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A99">Analyse 99

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A100">Analyse 100

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A101">Analyse 101

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A102">Analyse 102

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A103">Analyse 103

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A104">Analyse 104

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A105">Analyse 105

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A106">Analyse 106

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A107">Analyse 107

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A108">Analyse 108

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A109">Analyse 109

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A110">Analyse 110

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A111">Analyse 111

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A112">Analyse 112

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A113">Analyse 113

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A114">Analyse 114

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A115">Analyse 115

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A116">Analyse 116

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A117">Analyse 117

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A118">Analyse 118

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A119">Analyse 119

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A120">Analyse 120

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A121">Analyse 121

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A122">Analyse 122

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A123">Analyse 123

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A124">Analyse 124

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A125">Analyse 125

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A126">Analyse 126

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A127">Analyse 127

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A128">Analyse 128

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A129">Analyse 129

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A130">Analyse 130

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A131">Analyse 131

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A132">Analyse 132

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A133">Analyse 133

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A134">Analyse 134

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A135">Analyse 135

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A136">Analyse 136

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A137">Analyse 137

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A138">Analyse 138

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A139">Analyse 139

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A140">Analyse 140

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A141">Analyse 141

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A142">Analyse 142

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A143">Analyse 143

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A144">Analyse 144

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A145">Analyse 145

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A146">Analyse 146

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A147">Analyse 147

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A148">Analyse 148

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A149">Analyse 149

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A150">Analyse 150

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A151">Analyse 151

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A152">Analyse 152

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A153">Analyse 153

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A154">Analyse 154

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A155">Analyse 155

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A156">Analyse 156

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A157">Analyse 157

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A158">Analyse 158

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A159">Analyse 159

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A160">Analyse 160

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A161">Analyse 161

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A162">Analyse 162

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A163">Analyse 163

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A164">Analyse 164

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A165">Analyse 165

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A166">Analyse 166

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A167">Analyse 167

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A168">Analyse 168

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A169">Analyse 169

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A170">Analyse 170

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A171">Analyse 171

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A172">Analyse 172

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A173">Analyse 173

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A174">Analyse 174

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A175">Analyse 175

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A176">Analyse 176

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A177">Analyse 177

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A178">Analyse 178

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A179">Analyse 179

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A180">Analyse 180

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A181">Analyse 181

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A182">Analyse 182

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A183">Analyse 183

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A184">Analyse 184

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A185">Analyse 185

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A186">Analyse 186

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A187">Analyse 187

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A188">Analyse 188

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A189">Analyse 189

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A190">Analyse 190

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A191">Analyse 191

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A192">Analyse 192

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A193">Analyse 193

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A194">Analyse 194

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A195">Analyse 195

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A196">Analyse 196

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A197">Analyse 197

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A198">Analyse 198

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A199">Analyse 199

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A200">Analyse 200

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A201">Analyse 201

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A202">Analyse 202

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A203">Analyse 203

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A204">Analyse 204

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A205">Analyse 205

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A206">Analyse 206

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A207">Analyse 207

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A208">Analyse 208

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A209">Analyse 209

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A210">Analyse 210

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |               +--------------------------APPOS--------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A211">Analyse 211

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A212">Analyse 212

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A213">Analyse 213

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A214">Analyse 214

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A215">Analyse 215

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A216">Analyse 216

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A217">Analyse 217

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A218">Analyse 218

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A219">Analyse 219

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A220">Analyse 220

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A221">Analyse 221

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A222">Analyse 222

             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A223">Analyse 223

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A224">Analyse 224

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A225">Analyse 225

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A226">Analyse 226

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A227">Analyse 227

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A228">Analyse 228

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A229">Analyse 229

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A230">Analyse 230

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A231">Analyse 231

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A232">Analyse 232

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A233">Analyse 233

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A234">Analyse 234

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A235">Analyse 235

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A236">Analyse 236

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A237">Analyse 237

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A238">Analyse 238

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A239">Analyse 239

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A240">Analyse 240

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A241">Analyse 241

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A242">Analyse 242

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A243">Analyse 243

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A244">Analyse 244

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A245">Analyse 245

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A246">Analyse 246

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A247">Analyse 247

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A248">Analyse 248

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A249">Analyse 249

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A250">Analyse 250

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A251">Analyse 251

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A252">Analyse 252

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A253">Analyse 253

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A254">Analyse 254

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A255">Analyse 255

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A256">Analyse 256

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A257">Analyse 257

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A258">Analyse 258

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A259">Analyse 259

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A260">Analyse 260

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A261">Analyse 261

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A262">Analyse 262

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A263">Analyse 263

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A264">Analyse 264

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A265">Analyse 265

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A266">Analyse 266

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A267">Analyse 267

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A268">Analyse 268

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A269">Analyse 269

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +MOD_ATT:N-AD+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-ADJ (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A270">Analyse 270

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A271">Analyse 271

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |               +--------------------------APPOS--------------------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |               |                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A272">Analyse 272

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |               +--------------------------APPOS--------------------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |               |                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (bezafibrate,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A273">Analyse 273

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A274">Analyse 274

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A275">Analyse 275

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A276">Analyse 276

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A277">Analyse 277

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A278">Analyse 278

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A279">Analyse 279

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A280">Analyse 280

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A281">Analyse 281

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A282">Analyse 282

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A283">Analyse 283

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A284">Analyse 284

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A285">Analyse 285

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A286">Analyse 286

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A287">Analyse 287

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A288">Analyse 288

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A289">Analyse 289

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A290">Analyse 290

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A291">Analyse 291

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A292">Analyse 292

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A293">Analyse 293

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A294">Analyse 294

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A295">Analyse 295

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A296">Analyse 296

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A297">Analyse 297

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A298">Analyse 298

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A299">Analyse 299

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A300">Analyse 300

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A301">Analyse 301

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A302">Analyse 302

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A303">Analyse 303

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A304">Analyse 304

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A305">Analyse 305

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A306">Analyse 306

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A307">Analyse 307

                                                                                                                                  +------------------COMP:N-N(with)-----------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A308">Analyse 308

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A309">Analyse 309

                                                                                                                                  +------------------COMP:N-N(with)-----------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A310">Analyse 310

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A311">Analyse 311

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A312">Analyse 312

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A313">Analyse 313

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A314">Analyse 314

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A315">Analyse 315

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A316">Analyse 316

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A317">Analyse 317

                                                                                                                      +------------------------COMP:N-N(with)-----------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A318">Analyse 318

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A319">Analyse 319

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A320">Analyse 320

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A321">Analyse 321

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A322">Analyse 322

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A323">Analyse 323

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A324">Analyse 324

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A325">Analyse 325

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A326">Analyse 326

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A327">Analyse 327

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A328">Analyse 328

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A329">Analyse 329

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A330">Analyse 330

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A331">Analyse 331

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A332">Analyse 332

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A333">Analyse 333

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A334">Analyse 334

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        |          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A335">Analyse 335

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A336">Analyse 336

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A337">Analyse 337

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A338">Analyse 338

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A339">Analyse 339

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A340">Analyse 340

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A341">Analyse 341

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A342">Analyse 342

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A343">Analyse 343

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A344">Analyse 344

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A345">Analyse 345

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A346">Analyse 346

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A347">Analyse 347

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A348">Analyse 348

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A349">Analyse 349

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
                                                                                                                                  +------------------COMP:N-N(with)-----------------+                  |     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A350">Analyse 350

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A351">Analyse 351

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A352">Analyse 352

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A353">Analyse 353

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A354">Analyse 354

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------------COMP:N-N(of)------------------+        |                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A355">Analyse 355

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A356">Analyse 356

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A357">Analyse 357

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A358">Analyse 358

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A359">Analyse 359

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A360">Analyse 360

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A361">Analyse 361

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A362">Analyse 362

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A363">Analyse 363

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A364">Analyse 364

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                                                  
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A365">Analyse 365

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A366">Analyse 366

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A367">Analyse 367

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A368">Analyse 368

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A369">Analyse 369

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A370">Analyse 370

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A371">Analyse 371

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A372">Analyse 372

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A373">Analyse 373

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          |           +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |           |          +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(with) (cholestasis,knockout)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A374">Analyse 374

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A375">Analyse 375

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A376">Analyse 376

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+----------------COMP:N-N(of)----------------+     
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
COMP:N-N(of) (__SP__,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A377">Analyse 377

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A378">Analyse 378

             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +----------------------------COMP:N-N(of)----------------------------+     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                                            |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+------COMP:N-N(with)-----+                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
COMP:N-N(with) (__SP__,knockout)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A379">Analyse 379

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A380">Analyse 380

             +-------------------------------------------SUBJ:V-N------------------------------------------+          +------------------------COMP:N-N(with)-----------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         +---COMP:N-N(of)---+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
COMP:N-N(with) (cholestasis,knockout)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A381">Analyse 381

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A382">Analyse 382

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A383">Analyse 383

                                                                                                                                  +----------------------------COMP:N-N(of)----------------------------+     
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +------------------COMP:N-N(with)-----------------+                  |     
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                  |     
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                  |     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+          +MOD_ATT+     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
COMP:N-N(with) (liver,knockout)
COMP:N-N(of) (liver,__NODE__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
MOD_ATT:N-ADJ (__NODE__,__SP__)

name="reponse" value="A384">Analyse 384

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A385">Analyse 385

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A386">Analyse 386

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A387">Analyse 387

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+                         |                        
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+               +MOD_ATT:N+COMP:N-N(o+             
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |               |         |          |             
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A388">Analyse 388

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   +----------------COMP:V-N(from)----------------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                                 +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(from) (increase,__SP__)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A389">Analyse 389

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             +----------------------------------APPOS----------------------------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
APPOS (administration,period)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A390">Analyse 390

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A391">Analyse 391

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A392">Analyse 392

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A393">Analyse 393

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A394">Analyse 394

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
COMP:N-N(of) (percent,year)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A395">Analyse 395

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A396">Analyse 396

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A397">Analyse 397

                                                                                                           +-----------------------------COMP:V-N(with)-----------------------------+                        
             +-------------------------------------------SUBJ:V-N------------------------------------------+          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                                           |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A398">Analyse 398

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A399">Analyse 399

             +-------------------------------------------SUBJ:V-N------------------------------------------+                                                                                                 
             |                                  +-------------------COMP:N-N(of)------------------+        +-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+          |        |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |          |        |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+          |        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,year)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A400">Analyse 400

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A401">Analyse 401

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A402">Analyse 402

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A403">Analyse 403

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A404">Analyse 404

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A405">Analyse 405

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |                      +-----COMP:N-N(from)----+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |                      |          +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A406">Analyse 406

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A407">Analyse 407

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)

name="reponse" value="A408">Analyse 408

             +-------------------------------------------SUBJ:V-N------------------------------------------+-----------------------------COMP:V-N(with)-----------------------------+                        
             |                                  +-------------COMP:N-N(of)-------------+                   |          +-----------COMP:N-N(from)----------+                         |                        
             |                                  +-COMP:N-N(of)-+                       |                   |          |                      +-MOD_ATT:N-N+     +----------------OBJ:V-N---------------+     
   +MOD_ATT:N+--COMP:N-N(of)-+                  |        +MOD_A+              +MOD_ATT:+COMP:N-N(o+        +--OBJ:V-N-+COMP:N-N(of+          |     +MOD_AT+     |         +MOD_ATT:N+COMP:N-N(o+       |     
   |         |               |                  |        |     |              |        |          |        |          |           |          |     |      |     |         |         |          |       |     
 Oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases cholestasis of liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,bezafibrate)
COMP:N-N(of) (dosage,percent)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-ADJ (percent,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,year)
SUBJ:V-N (increase,administration)
OBJ:V-N (increase,cholestasis)
COMP:V-N(with) (increase,knockout)
COMP:N-N(of) (cholestasis,liver)
COMP:N-N(from) (cholestasis,__SP__)
MOD_ATT:N-N (__SP__,male)
MOD_ATT:N-ADJ (__SP__,mutant)
OBJ:V-N (with,__NODE__)
MOD_ATT:N-ADJ (knockout,homozygous)
COMP:N-N(of) (knockout,__SP__)